(NYSE: BDX) Becton Dickinson & Co's forecast annual revenue growth rate of 4.52% is not forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 8.48%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10%.
Becton Dickinson & Co's revenue in 2024 is $19,716,000,000.On average, 8 Wall Street analysts forecast BDX's revenue for 2024 to be $5,842,189,311,409, with the lowest BDX revenue forecast at $5,834,789,011,969, and the highest BDX revenue forecast at $5,849,201,764,179. On average, 8 Wall Street analysts forecast BDX's revenue for 2025 to be $6,175,741,783,276, with the lowest BDX revenue forecast at $6,135,896,173,491, and the highest BDX revenue forecast at $6,197,206,004,128.
In 2026, BDX is forecast to generate $6,505,125,047,935 in revenue, with the lowest revenue forecast at $6,448,312,157,832 and the highest revenue forecast at $6,533,569,063,827.